With the 100 percent tariff on patented pharmaceuticals set to bite on September 29, importers race the clock while drugmakers weigh onshoring deals and pricing concessions
WASHINGTON, September 8, 2026. Three weeks from today, the United States will begin collecting a 100 percent tariff on imported patented pharmaceuticals and their active ingredients from most of the world’s drugmakers, the steepest sectoral duty in modern American trade policy. With the September 29 effective date now inside most companies’ final shipping windows, the pharmaceutical supply chain has entered a period of intense, and in some corners frantic, preparation: import volumes are being pulled forward, customs classifications are being scrubbed, and companies that missed the government’s deadline for negotiated relief are confronting the full weight of the headline rate.
The tariff stems from Proclamation 11020, signed by President Trump on April 2 under Section 232 of the Trade Expansion Act of 1962, following a Commerce Department investigation that concluded pharmaceutical imports, in the proclamation’s words, “threaten to impair the national security and economy” of the United States. The White House cited Food and Drug Administration data showing that as of 2025, 53 percent of patented medicines distributed in the United States were produced overseas, and only 15 percent of patented active pharmaceutical ingredients by volume were manufactured domestically.
For a group of the largest multinational drugmakers named in an annex to the proclamation, companies already engaged in the administration’s first wave of most favored nation pricing negotiations, the duties took effect on July 31. For everyone else, the switch flips at 12:01 a.m. on September 29. The coming three weeks are, in effect, the last unencumbered window for the rest of the industry.
How the Policy Got Here
The road to September 29 runs through the Supreme Court. In late February, the Court’s decision in Learning Resources v. Trump struck down the administration’s IEEPA-based global tariffs, momentarily throwing the entire tariff agenda, including its pharmaceutical ambitions, into doubt. Industry publications captured the mood of that moment in headlines asking whether the tariffs were off; PharmaSource, a manufacturing industry outlet, published its analysis under the title “Trump’s Tariffs Are Off, Or Are They? What Pharma Does Next.” The answer came quickly. Stripped of IEEPA, the administration pivoted to the sectoral authority of Section 232, which the Supreme Court’s ruling left untouched, and to Section 301. The Commerce Department’s pharmaceutical investigation, opened in 2025, supplied the national security findings, and the April 2 proclamation converted them into the 100 percent duty now three weeks from general effect.
The proclamation’s two-speed calendar was itself a negotiating instrument. The 16 large drugmakers named in Annex III, the companies already at the table in the administration’s first wave of most favored nation pricing talks, saw their tariff exposure begin on July 31, nearly two months before everyone else. That sequencing gave the biggest companies the strongest incentive to close MFN and onshoring deals first, establishing templates, and public pricing precedents, that the administration could then press on the rest of the industry. Several of those first-wave companies announced US investment expansions in the weeks around their effective date, which the White House has folded into its 400 billion dollar tally of claimed commitments.
The choice of the September 29 date for the general population of importers was not explained in the proclamation, but its effect is now visible: it gave mid-sized and smaller companies one full quarter to seek relief, restructure supply chains or accelerate imports, and it placed the deadline squarely inside the fourth-quarter planning cycle for an industry that sets US launch prices and contracting terms for the coming year in the autumn.
A Headline Rate With a Long List of Exceptions
The 100 percent figure is the most dramatic number in the proclamation, but trade lawyers who have dissected the document consistently emphasize how much of the market it does not touch. The law firm Ropes & Gray, in a client analysis titled “100% On Brand,” catalogued exemptions broad enough that the effective tariff burden on the overall US medicine supply will land far below the headline rate.
Generic drugs and biosimilars, which account for more than 90 percent of US prescriptions filled, are exempt, though the proclamation requires the administration to reassess their status within a year, and a separate July action gave generic manufacturers a two-year runway to reshore production before facing their own duties, according to the industry publication PharmaSource. Also excluded are orphan drugs where every approved indication carries an orphan designation, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody-drug conjugates, medical countermeasures against chemical, biological, radiological and nuclear threats, and animal health products, provided the goods originate in a country holding a trade and security framework agreement with the United States or meet an urgent domestic health need.
Country-level arrangements soften the blow further for allied producers. Products from the European Union, Japan, South Korea, Switzerland and Liechtenstein face a 15 percent rate under existing trade deals rather than the full 100 percent. Medicines manufactured in the United Kingdom currently carry a 10 percent duty, with the rate set to fall to zero as required by the US-UK pharmaceutical partnership agreement, which London secured in exchange for changes to National Health Service medicines pricing that improve access for novel treatments. The UK is so far the only country with a negotiated pathway to a zero rate.
Two Escape Hatches: Onshoring and MFN Pricing
For companies outside the exempt categories, the proclamation built two relief tracks, both of which reward behavior the administration wants: moving production to America and cutting US prices.
The first track runs through the Commerce Department. Companies that secured Secretary of Commerce approval for a company-specific onshoring agreement, committing to detailed investment and production milestones on US soil, qualify for a reduced 20 percent tariff rate instead of 100 percent, a concession that lasts until April 2, 2030, when the rate snaps back to the full level. The department published its application procedures in the Federal Register on May 13 and gave companies just 30 days, until June 12, to apply, a compressed window that the law firm Skadden flagged at the time as a critical deadline. Applications required detailed disclosure of investments, production plans and compliance commitments, and the proclamation authorizes Commerce to monitor progress through periodic reports, with retroactive reimposition of the full tariff in cases of fraud or misrepresentation.
The second track is pricing. Companies that both hold an approved onshoring plan and have fully executed a most favored nation pricing agreement, aligning their US prices with the lowest prices charged in other developed markets, pay no tariff at all until January 20, 2029. That structure makes the tariff program inseparable from the administration’s broader drug pricing agenda: the duty is the stick, and tariff-free access to the world’s most profitable pharmaceutical market is the carrot for pricing concessions that drugmakers have resisted for decades.
The White House has claimed vindication for the approach, stating that the threat of tariffs has already driven 400 billion dollars in announced pharmaceutical investment commitments. Examples cited include Johnson & Johnson’s 55 billion dollar US manufacturing commitment through 2029 and CSL’s 1.5 billion dollar expansion of its plasma-derived therapies plant in Kankakee, Illinois.
The Three-Week Scramble
For importers, the days between now and September 29 are dominated by logistics. Because Section 232 duties attach at the time of entry, product that clears US customs before the effective date enters at today’s rates regardless of when it was ordered. That has produced a familiar pattern, one documented across earlier tariff waves: accelerated shipments, chartered freight and warehouse stockpiling. Industry analysts at IntuitionLabs, in a review of the sector’s response, described the supply chain effects of the 2026 pharmaceutical tariffs as including stockpiling, fragmentation and geographic shifts in sourcing.
Pharmaceutical stockpiling has natural limits that make the current scramble more complicated than it was for, say, steel. Many biologics require cold-chain storage with finite capacity. Products carry expiration dating that constrains how much inventory can usefully be built. And Food and Drug Administration rules tie specific manufacturing sites to specific approvals, meaning an importer cannot simply resource a molecule to a tariff-favored country without regulatory work measured in months or years.
For smaller biotech companies, the exposure is existential rather than logistical. Public company filings this year, including quarterly reports from clinical-stage firms such as Akebia Therapeutics and Dyne Therapeutics, have begun disclosing pharmaceutical tariff exposure as a material risk factor, reflecting a reality that clinical-stage companies with single overseas manufacturing relationships, often with European or Asian contract manufacturers, have neither the volume to justify a US plant nor the leverage to negotiate an onshoring agreement. For these firms, the choice on September 29 is stark: absorb a doubling of cost of goods on patented product, or attempt a manufacturing transfer that regulators and capacity constraints may not permit on any near-term timeline.
What It Means for Prices and Patients
The consumer-facing question, whether Americans will pay more for medicine, has no single answer because the tariff’s design deliberately shields the highest-volume segment of the market. With generics exempt and more than 90 percent of prescriptions filled generically, the immediate impact concentrates on branded, patented therapies, the segment where list prices are highest and where insurers, pharmacy benefit managers and employers ultimately absorb and redistribute costs.
Analysts advising employer health plans, including the pharmacy analytics firm Truveris, have cautioned that branded drug tariffs can flow through to plan sponsors in the form of higher net costs even when patient copays are insulated in the short run. The administration’s counterargument is that the MFN pricing track will more than offset tariff pass-through for participating companies, since those firms are contractually committed to lowering US prices toward international benchmarks in exchange for their zero rate.
The policy’s defenders also point to national security logic that commands some bipartisan sympathy: the concentration of API production in a small number of overseas hubs has been flagged by successive administrations as a genuine vulnerability, exposed most vividly during the pandemic era. Critics respond that a 100 percent tariff is a blunt instrument for a problem that targeted subsidies, stockpiles and approval reforms could address at lower cost, and that Section 232 duties, once imposed, are notoriously durable. A Section 232 tariff remains in force until a president affirmatively finds the national security threat has passed, and no expiration date exists in the proclamation for the tariff itself, only for the relief tracks.
Global Ripples: Ireland, India and the API Hubs
For exporting countries, the tariff redraws one of the most lopsided maps in world trade. Ireland, whose pharmaceutical exports to the United States rank among the largest bilateral drug flows anywhere, ships predominantly branded, patented product from plants operated by American multinationals, exactly the category the 100 percent duty targets. The EU’s negotiated 15 percent rate softens the exposure substantially, but a 15 percent duty on high-value biologics still represents a cost measured in billions across the Irish industry, and Irish development agencies have spent the year courting the reinvestment decisions that will determine whether future capacity lands in Cork or in North Carolina.
Switzerland’s rate, also 15 percent under its framework agreement, matters for the same reason: the country is home to Roche and Novartis and to a dense contract manufacturing sector. Japan and South Korea, likewise at 15 percent, have significant and growing biologics export positions. The United Kingdom’s pathway to zero, purchased with NHS pricing concessions, gives British manufacturing sites a tariff advantage over EU rivals that trade advisers expect to feature in the next round of corporate site-selection decisions, an outcome London’s negotiators openly sought.
India and China, the world’s dominant producers of generic drugs and active ingredients, sit largely outside the current tariff’s reach because of the generics exemption, a fact that cuts against the policy’s stated supply security rationale and that the administration has acknowledged by ordering a reassessment of the exemption within a year. The separate two-year reshoring runway announced for generic manufacturers in July signals where that reassessment is likely heading. If generics duties follow in 2028, the cost pressure would land on the segment of the market with the thinnest margins and the most fragile supply chains, which is precisely why the administration deferred it and why generic manufacturers and hospital groups are already lobbying against it.
Stakeholders Take Sides
Reaction to the approaching deadline has divided along predictable but increasingly vocal lines. The research-based industry’s trade association has argued throughout the year that tariffs on medicines raise costs without accelerating onshoring, pointing out that new pharmaceutical plants take five to ten years to permit, build and validate, a timeline no tariff can compress. Companies have largely declined to fight publicly, preferring to negotiate; the flow of announced US investments, from Johnson & Johnson’s 55 billion dollar program to CSL’s Kankakee expansion, reflects a calculation that visible commitment buys better treatment under the relief tracks.
Hospital systems and pharmacists have focused on shortage risk, warning that even exempt categories can be disrupted when upstream ingredients cross tariff lines, and that sterile injectables, the chronic weak point of the US drug supply, tolerate cost shocks poorly. Employer coalitions and pharmacy benefit consultancies, including analyses circulated by Truveris, have warned plan sponsors to expect branded cost pressure in 2027 renewals. On the other side, domestic manufacturing advocates and several unions have welcomed the program as the first policy in decades to move real capital into American drug production, citing the same 400 billion dollar commitment figure the White House promotes.
Wall Street’s read has been more transactional: pharmaceutical equities have generally outperformed on days the administration emphasized the relief tracks, reflecting investor confidence that the largest companies will secure zero or 20 percent rates, while contract manufacturers with US capacity have traded as beneficiaries of the onshoring wave. The market, in other words, has priced the tariff as a negotiation, not a wall.
The Compliance Trap Ahead
Customs practitioners are warning importers about several traps in the final stretch. Classification is the first: the line between a patented pharmaceutical and an exempt category is drawn with tariff schedule provisions and annex lists, and misclassification in either direction carries risk, of overpayment on the one hand and of penalties and back duties on the other. Companies whose products sit near category boundaries, combination products, drugs with both orphan and non-orphan indications, and biologic-adjacent therapies, are being advised to seek binding rulings or written advice before the effective date rather than after.
Origin is the second trap. The country-based rates, 15 percent for EU and Japanese product, 10 percent and falling for the UK, turn on origin determinations that are more complicated for pharmaceuticals than almost any other product, because a single medicine may involve API synthesis in one country, formulation in a second and packaging in a third. Trade counsel expect a wave of origin engineering, and an eventual wave of CBP enforcement scrutinizing it.
The third trap is documentation for the relief tracks. Companies operating under onshoring agreements must be prepared to demonstrate milestone compliance in periodic progress reports, knowing that the proclamation authorizes retroactive tariff reimposition for misrepresentation. An onshoring commitment made optimistically in June becomes a legal exposure in September if groundbreaking dates and capital deployment schedules slip.
The Wider Trade Context
The pharmaceutical action does not stand alone. It is one pillar of a rebuilt tariff architecture that the administration erected after the Supreme Court’s February decision striking down its IEEPA-based global tariffs, a rebuild that has leaned heavily on Section 232 sectoral actions, including semiconductors, and on new Section 301 duties covering 60 economies that took effect in July. Commerce Secretary Howard Lutnick has explicitly described the pharmaceutical program, tariff relief in exchange for US manufacturing and MFN pricing, as the template for the semiconductor tariffs now in development, telling interviewers this month that observers should expect the chip program to mirror the pharma deal structure.
That makes the next three weeks a test case with consequences far beyond medicine. If the September 29 deadline arrives with the major exempted categories holding, the onshoring track functioning and no acute shortages, the administration will read the result as proof that maximalist sectoral tariffs paired with negotiated relief can bend global industries toward American production. If instead the deadline brings supply disruptions, price spikes in the branded segment or a wave of litigation, the pharmaceutical program will become the cautionary tale cited in every comment docket on the tariffs still to come.
Either way, importers should assume the duty arrives on schedule. Nothing in the administration’s public posture over the past week suggests a delay, and the infrastructure for collection, the tariff schedule provisions, the annex lists and the CBP guidance, is already in place. The industry has known the date since April. In three weeks, the theory becomes an invoice.